ABVC BioPharma
ABVC · Nasdaq · United States
Share price · ABVC
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ABVC's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 15 Oct 2026-8.6%
Nothing announced by ABVC that day or the session before.
- 3 Sep 2026+15.7%
Nothing announced by ABVC that day or the session before.
- 9 Jul 2026-28.2%
Nothing announced by ABVC that day or the session before.
- 1 Jul 2026+12.0%
Nothing announced by ABVC that day or the session before.
- 26 May 2026+13.2%
Nothing announced by ABVC that day or the session before.
- 6 Apr 2026+27.5%
Nothing announced by ABVC that day or the session before.
- 1 Apr 2026+11.3%
Nothing announced by ABVC that day or the session before.
- 2 Mar 2026+13.0%
Nothing announced by ABVC that day or the session before.
- 23 Feb 2026-7.3%
Nothing announced by ABVC that day or the session before.
- 5 Feb 2026-15.8%
Nothing announced by ABVC that day or the session before.
Share of unusual movement by asset
For each asset, the share of ABVC's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 10% |
| Sessions with no dated event | — | 90% |
No dated announcements about its assets since 2 Jul 2024.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Polygalae radix extract (active components: tenuifolin, polygalasaponins, etc.)Botanical | Major Depressive DisorderAttention Deficit Hyperactivity Disorder |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | <$0.1M | <$0.1M+ $0.1M short-term inv. | —-$0.4M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | <$0.1M | <$0.1M+ $0.1M short-term inv. | $0.7M-$0.2M operating cash flow | report ↗ |
| 2026-Q1 | — | <$0.1M | $0.1M+ $0.1M short-term inv. | $1.6M-$0.9M operating cash flow | report ↗ |
| 2025-Q3 | $0.8M | <$0.1M | $0.8M+ $0.1M short-term inv. | $1.3M-$0.1M operating cash flow | report ↗ |
| 2025-Q2 | — | <$0.1M | $1.1M+ $0.1M short-term inv. | $2.3M-$0.9M operating cash flow | report ↗ |
| 2025-Q1 | — | <$0.1M | $0.8M+ $0.1M short-term inv. | $0.8M-$0.5M operating cash flow | report ↗ |
| 2024-Q3 | $0.4M | <$0.1M | $0.8M+ $0.1M short-term inv. | $0.2M$0.2M operating cash flow | report ↗ |
| 2024-Q2 | $0.1M | <$0.1M | $0.7M+ $0.1M short-term inv. | $0.9M-$1.0M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $0.1M | $0.7M+ $0.1M short-term inv. | $3.9M-$0.5M operating cash flow | report ↗ |
| 2023-Q3 | <$0.1M | $0.1M | $1.1M+ $0.1M short-term inv. | $3.3M-$1.4M operating cash flow | report ↗ |
| 2023-Q2 | <$0.1M | $0.5M | $0.7M+ $0.1M short-term inv. | $2.3M-$0.9M operating cash flow | report ↗ |
| 2023-Q1 | $0.1M | $0.3M | $1.8M+ $0.1M short-term inv. | $1.8M-$1.5M operating cash flow | report ↗ |
| 2022-Q3 | <$0.1M | $0.3M | $2.0M+ $0.1M short-term inv. | $3.7M-$0.5M operating cash flow | report ↗ |
| 2022-Q2 | $0.3M | $0.5M | $3.6M+ $0.1M short-term inv. | $1.9M-$3.4M operating cash flow | report ↗ |
| 2022-Q1 | <$0.1M | $0.4M | $3.4M+ $0.1M short-term inv. | $6.1M-$3.0M operating cash flow | report ↗ |
| 2021-Q3 | $0.1M | $0.3M | $4.5M+ $0.1M short-term inv. | $1.9M-$2.7M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $0.1M | $1.3M+ $0.1M short-term inv. | $2.0M-$3.0M operating cash flow | report ↗ |
ABVC BioPharma did not disclose revenue for fiscal 2025, compared with $0.51M in the prior year. R&D spend was $0.12M, down 33.3% YoY, while cash and equivalents stood at $1.33M. The company reported a net loss of $7.91M and a quarterly net burn of $7.91M.
Management highlighted a 179% YoY increase in total assets to $21.06M, largely driven by a rise in net property and equipment to $12.84M and strategic land acquisitions in Taiwan, including properties valued at $4.6M and approximately $8.0M. Core programs remain licensed to subsidiaries and related parties (CNS to AiBtl BioPharma, oncology to OncoX BioPharma, and ophthalmology to ForSeeCon Eye Corporation), a structure meant to reduce direct clinical cash burn while retaining licensing economics and equity participation. The pipeline includes six drugs and one medical device, ABV-1701/Vitargus, and the release did not provide financial guidance.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $0.5M | $0.2M | $0.9M+ $0.1M short-term inv. | $1.2M-$1.8M operating cash flow | report ↗ |
| 2023-FY | $0.1M | $1.1M | $0.7M+ $0.1M short-term inv. | $2.6M-$4.2M operating cash flow | report ↗ |
| 2022-FY | $1.0M | $2.7M | $1.4M+ $0.1M short-term inv. | $4.1M-$7.4M operating cash flow | report ↗ |
| 2021-FY | $0.4M | $1.0M | $6.6M+ $0.1M short-term inv. | $3.0M-$7.6M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2012-01-27 | Stolz Kevin Patrick · VP & Controller | Award / grant | 6,250 | — | — | Form 4 |
| 2011-05-25 | Krotine Frank Thomas · COO | Award / grant (derivative) | 300,000 | $0.20 | $60K | Form 4 |
| 2011-05-11 | Ramsey Sally Judith · director, VP New Product Development | Award / grant (derivative) | 2,100,000 | $0.20 | $420K | Form 4 |
| 2011-05-11 | Crockett Robert G · Chief Executive Officer | Award / grant (derivative) | 1,800,000 | $0.20 | $360K | Form 4 |
| 2011-05-11 | IANNOTTI DANIEL V · VP, General Counsel & Secretar | Award / grant (derivative) | 300,000 | $0.20 | $60K | Form 4 |
| 2011-05-11 | Stolz Kevin Patrick · CFO & Controller | Award / grant (derivative) | 50,000 | $0.20 | $10K | Form 4 |
| 2010-08-12 | Juliano James · director, 10% owner | Award / grant (derivative) | 100,000 | $0.10 | $10K | Form 4 |
| 2010-05-11 | Nirta Joseph · director | Open-market purchase | 10,000 | $0.15 | $2K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 13 reporting institutions held 0.8M shares ($792K, 3.1% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | GEODE CAPITAL MANAGEMENT, LLC | 221,169 | $215K |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 190,574 | $185K |
| 3 | VANGUARD FIDUCIARY TRUST CO | 97,363 | $94K |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 95,100 | $92K |
| 5 | STATE STREET CORP | 72,800 | $71K |
| 6 | BlackRock, Inc. | 56,442 | $55K |
| 7 | NORTHERN TRUST CORP | 32,087 | $31K |
| 8 | TWO SIGMA SECURITIES, LLC | 21,023 | $20K |
| 9 | DIMENSIONAL FUND ADVISORS LP | 12,227 | $12K |
| 10 | Squarepoint Ops LLC | 10,547 | $10K |
| 11 | Tower Research Capital LLC (TRC) | 5,423 | $5K |
| 12 | UBS Group AG | 1,771 | $2K |
| 13 | ROYAL BANK OF CANADA | 17 | $0 |